Litcius/Paper detail

Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile

Paolo A. Ascierto, Anna Maria Di Giacomo, Vanna Chiarion‐Sileni, Paola Queirolo, Francesco Spagnolo, Federica De Galitiis, Francesco Cognetti, Mario Mandalà, Massimo Guidoboni, Gaetana Rinaldi, Roberta Depenni, Francesca Consoli, Teresa Troiani, Michele Guida, Riccardo Marconcini, Pier Francesco Ferrucci, Sabino Strippoli, Paolo Fava, Barbara Merelli, Ester Simeone, Lorenza Di Guardo, Diana Giannarelli, Massimo Di Maïo, Pietro Quaglino, Michele Del Vecchio

2023European Journal of Cancer10 citationsDOIOpen Access PDF

Topics & Concepts

NivolumabMedicineIpilimumabInternal medicineAdverse effectPopulationMelanomaStage (stratigraphy)AdjuvantOncologyExpanded accessCohortCancerSurgeryImmunotherapyCancer researchPaleontologyEnvironmental healthBiologyCutaneous Melanoma Detection and ManagementCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile | Litcius